It's gone from the corporate pipeline chart. This was deCODES big play.
anonymous Guest anonymous   May 31, 2018 at 03:02: PM #1 anonymous Guest It's gone from the corporate pipeline chart. This was deCODES big play.
anonymous Guest anonymous   May 31, 2018 at 07:45: PM #2 anonymous Guest Asialoglycoprotein receptor was a questionable target to begin with. It's highly expressed in the liver and its function is to remove recycle damaged glycoproteins in the plasma. How could antagonizing that have any positive cardiovascular benefit?
Asialoglycoprotein receptor was a questionable target to begin with. It's highly expressed in the liver and its function is to remove recycle damaged glycoproteins in the plasma. How could antagonizing that have any positive cardiovascular benefit?
anonymous Guest anonymous   May 31, 2018 at 09:31: PM #3 anonymous Guest At investor meeting, SH made a big deal about "target X". What a disappointment.
anonymous Guest anonymous   May 31, 2018 at 10:31: PM #4 anonymous Guest R&D leadership demanded it, to try to show value from decode
anonymous Guest anonymous   Jun 01, 2018 at 01:17: AM #5 anonymous Guest anonymous said: R&D leadership demanded it, to try to show value from decode Click to expand... Too bad Amgen R+D overemphasizes molecular biology and underemphasizes biochemistry. If not for that, they would have known better.
anonymous said: R&D leadership demanded it, to try to show value from decode Click to expand... Too bad Amgen R+D overemphasizes molecular biology and underemphasizes biochemistry. If not for that, they would have known better.